Generic name · Gastroenterology / Integrin
Vedolizumab J-Code / HCPCS Code
In short
Vedolizumab is billed under HCPCS J3380 — Injection, vedolizumab, 1 mg. One billing unit is 1 mg.
Reference
- Code
- J3380 — Injection, vedolizumab, 1 mgMed-Code curated
- Billing unit
- 1 mg
- Same code in the directory
- Entyvio
- Pharmacologic class
- Integrin Receptor AntagonistFrom the FDA listings below
- J-code category
- Gastroenterology / Integrin
FDA-listed products
Finished products whose name and route match this directory entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Entyviovedolizumab | Vedolizumab 300 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | Takeda Pharmaceuticals America, Inc. | 64764-300 |
Other products with this name
Same name but a different route, formulation or combination — the code above does not apply to these.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Entyviovedolizumab | Vedolizumab 108 mg/.68mL | Injection, SolutionSubcutaneous | Takeda Pharmaceuticals America, Inc. | 64764-107 |
| ENTYVIO Penvedolizumab | Vedolizumab 108 mg/.68mL | Injection, SolutionSubcutaneous | Takeda Pharmaceuticals America, Inc. | 64764-108 |
NDCs billed under J3380
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 1 NDC to J3380 for Entyvio. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Entyvio | 64764-0300-20 | Takeda Pharmaceuticals America, Inc. | 1 | 300 |